Table 2.

Summary of three independent studies, using molecular profiling (MammaPrint and BluePrint⁶⁷) as a predictive marker for chemo-sensitivity. In each study, the rate of pathologic complete response is given of the total population of patients in each intrinsic subtype. As a summary of all 3 studies, a percentage is given for each subtype from all patients enrolled in these 3 studies in the far right hand column. The luminal subtypes clearly have less chemo-sensitivity compared with HER2 and basal subtypes as shown by the endpoint pCR.

	STRAVER49		SOMLO62		HESS63		TOTAL
	n	pCR	n	pCR	n	pCR	n	pCR	%
Luminal-type/MP low risk	21	0	14	1	29	1	64	2	3%
Luminal-type/MP high risk	67	3	16	0	53	6	136	9	7%
HER2-type	41	13	18	10	24	12	83	35	42%
Basal-type	38	13	20	4	27	15	85	44	52%